BioSpace News Archive

Fenebrutinib in a mid-phase trial reduced brain legions in relapsing forms of multiple sclerosis, the company reported. It is the only reversible BTK inhibitor currently in Phase III MS trials.

Less than two years after announcing the launch of its clinical trial services business, CVS Health reported that it will shut down the division by the end of 2024.

Athenex announced it will lay off 79 employees in Buffalo and 44 employees in Clarence as a result of the Chapter 11 filing.

The Phase III trial met its primary endpoint, a significant reduction of phenylalanine levels in the blood, with no severe adverse events reported, PTC Therapeutics reported Wednesday.

In a 12-2 vote with two abstentions, the advisers said the benefits did not outweigh the risks.

The $75 million deal will leverage Scribe’s CRISPR technologies to develop gene therapies for neurological and neuromuscular disorders. Scribe previously struck deals with Biogen and Sanofi.

In the heart of one of the most innovative hubs in the country, biotech jobs in San Francisco abound, providing ample opportunity for job seekers.

Genentech, a member of the Roche Group, announced positive results from the Phase II FENopta study evaluating investigational oral fenebrutinib in adults with relapsing forms of multiple sclerosis.

Jiangsu Recbio Technology Co., Ltd. is pleased to announce that, MSCI announced the results of the semi-annual review of the MSCI Global Small Cap Indexes on May 12, 2023, and the Company has been selected as a constituent of the MSCI China Small Cap Index, with effect from the close of market on May 31, 2023.

CEO Johan Löf and CFO Henrik Bergentoft will present RaySearch’s interim report for January-March 2023 at a webcast to be held in English on Wednesday, May 17, 2023 at 10:00-10:30 a.m. CEST.